SCHEMBL1817756

SCHEMBL1817756

CC1(C)OCC(C)(C(=O)OC(=O)c2c(Cl)cc(Cl)cc2Cl)CO1

nearest known ligand 0.40

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.40
LMNA P02545 2/20 0.40
MAPT P10636 2/20 0.40
SPR P35270 11/20 0.39
HTT P42858 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
HCRTR1 O43613 1/20 0.31
HCRTR2 O43614 1/20 0.31
MAPK1 P28482 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6899970 0.84 LMNA (0.35) KMT2ALMNAMAPTSPRHTT
SCHEMBL7734302 0.80 LMNA (0.34) KMT2ALMNAMAPTSPRHTT
SCHEMBL6899995 0.79 LMNA (0.37) KMT2ALMNAMAPTSPR
SCHEMBL15799985 0.75 RAB9A (0.34) KMT2ALMNAMAPTHTTNPSR1
SCHEMBL432792 0.74 KMT2A (0.52) KMT2ALMNAMAPTSPRHTT
SCHEMBL493850 0.72 MAPT (0.45) KMT2ALMNAMAPTSPRHTT
SCHEMBL7733528 0.72 KCNA4 (0.37)
SCHEMBL435036 0.71 KMT2A (0.44) KMT2ALMNAMAPTSPRHTT
SCHEMBL435037 0.71 KMT2A (0.44) KMT2ALMNAMAPTSPRHTT
SCHEMBL16675316 0.69 KMT2A (0.37) KMT2ALMNAMAPTSPR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8754207-B2 Process for the preparation of rapamycin derivatives CADILA HEALTHCARE LIMITED (IN) 2014-06-17 US claimed
US-20120202988-A1 PROCESS FOR THE PREPARATION OF RAPAMYCIN DERIVATIVES CADILA HEALTHCARE LIMITED (IN) 2012-08-09 US claimed
EP-2480557-A2 PROCESS FOR THE PREPARATION OF RAPAMYCIN DERIVATIVES Cadila Healthcare Limited (IN) 2012-08-01 EP claimed
WO-2011051960-A2 PROCESS FOR THE PREPARATION OF RAPAMYCIN DERIVATIVES CADILA HEALTHCARE LIMITED (IN) 2011-05-05 WO claimed
US-8754207-B2 Process for the preparation of rapamycin derivatives CADILA HEALTHCARE LIMITED (IN) 2014-06-17 US disclosed
US-8258299-B2 Process for preparation of temsirolimus Chungwa Chemical Synthesis & Biotech Co., Ltd. (TW) 2012-09-04 US disclosed
US-20120202988-A1 PROCESS FOR THE PREPARATION OF RAPAMYCIN DERIVATIVES CADILA HEALTHCARE LIMITED (IN) 2012-08-09 US disclosed
US-20100249415-A1 Process for preparation of temsirolimus CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO., LTD. (TW) 2010-09-30 US disclosed
US-7202256-B2 Proline CCI-779, production of and uses therefor, and two-step enzymatic synthesis of proline CCI-779 and CCI-779 WYETH (US) 2007-04-10 US disclosed
US-7202256-B2 Proline CCI-779, production of and uses therefor, and two-step enzymatic synthesis of proline CCI-779 and CCI-779 WYETH (US) 2007-04-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249415-A1 Process for preparation of temsirolimus RICTOR, MTOR, MLST8 KMT2A 1942/4885LMNA 3396/4885MAPT 2047/4885
US-20120202988-A1 PROCESS FOR THE PREPARATION OF RAPAMYCIN DERIVATIVES RICTOR, MTOR, RPTOR KMT2A 3567/4885LMNA 4108/4885MAPT 3593/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.